Stoke Therapeutics, Inc.STOKNASDAQ
Loading
EV to Sales: Premium ValuationElevated
Percentile Rank75
3Y CAGR-21.3%
Studio
Year-over-Year Change

Enterprise value to sales ratio

3Y CAGR
-21.3%/yr
Annual compound
Percentile
P75
Within normal range
vs 3Y Ago
0.5x
Contraction
Streak
1 yr
Consecutive declineElevated
PeriodValueYoY Change
20259.74-24.3%
202412.86+168.6%
20234.79-76.0%
202219.98-
20210.00-
20200.00-
20190.00-
20180.00-
20170.00-